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Abstract We have previously established a first whole
genome transcriptomic profile of sporadic Parkinson’s
disease (PD). After extensive brain tissue-based validation
combined with cycles of iterative data analysis and by
focusing on the most comparable cases of the cohort, we
have refined our analysis and established a list of 892
highly dysregulated priority genes that are considered to
form the core of the diseased Parkinsonian metabolic
network. The substantia nigra pathways, now under
scrutiny, contain more than 100 genes whose association
with PD is known from the literature. Of those, more than
40 genes belong to the highly significantly dysregulated
group identified in our dataset. Apart from the complete list
of 892 priority genes, we present pathways revealing PD
‘hub’ as well as ‘peripheral’ network genes. The latter
include Lewy body components or interact with known PD
genes. Biological associations of PD with cancer, diabetes
and inflammation are discussed and interactions of the
priority genes with several drugs are provided. Our study
illustrates the value of rigorous clinico-pathological corre-
lation when analysing high-throughput data to make
optimal use of the histopathological phenome, or morpho-
nome which currently serves as the key diagnostic
reference for most human diseases. The need for systematic
human tissue banking, following the highest possible
professional and ethical standard to enable sustainability,
becomes evident.
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Introduction
Our understanding of Parkinson’s disease (PD) is largely
incomplete. However, the pace of discovery in this field is
rapidly accelerating. It took more than 100 years for the key
region of neuronal damage, the substantia nigra to be
identified [1], and it took almost 80 years for the first
disease-causing mutation to be discovered [2]. Not even
10 years later, the first whole genome transcriptome
analysis had been performed [3], and a number of other
microarray studies focusing on known sequences were
carried out (e.g. [4–6]). We now provide the complete list
of 892 highly dysregulated PD nigral genes derived from a
brain tissue-validated whole genome expression microarray
data set. In addition, predicted interactions of a number of
these genes are reported as potential drug targets. We would
like to emphasise that the neurohistological validation that
is so crucial for our work and which has already led to the
identification of two novel Lewy body components pre-
dicted on the basis of this dataset [7, 8] could not have been
performed without generous brain donations. In addition,
the iterative analysis performed combining histological
phenome (morphonome) data and clinical criteria within
silico data mining would not have been possible without
significant advances in computing, notably virtual machine
technology. It is readily apparent that a publication of this
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format requires the Internet as it would not have been
possible to publish its almost 3,200 hyperlinked files on
paper, which are provided as electronic supplemental
material.
PD is a severely disabling neurodegenerative disorder
second in frequency only to Alzheimer’s disease and has a
significant socio-economic impact. Unlike in Alzheimer’s
disease, however, the brain region taking the brunt of the
disease process is rather well circumscribed. In addition,
there is widespread consensus on diagnostic criteria both
clinically and neuropathologically (http://www.ICDNS.org).
This is at least in part due to the fact that the leading motor
symptoms are less complex and easier to recognize and
define than the clinical signs in disorders mainly affecting
higher brain functions such as cognition. Furthermore, there
is symptomatic treatment for PD pointing to key pathways
involved. All these are important prerequisites when
working with high throughput technologies such as micro-
arrays which require precise tissue sampling because the
procedures employed are both laborious and expensive.
Major known pathways involved in PD include the
ubiquitin-proteasome system dysfunction of which may
lead to abnormal protein deposition, mitochondrial failure
and decreased expression of synaptic proteins [6, 9–11].
Oxidative stress has been traditionally implicated in the
aetiology of the disease but the changes observed could be
secondary. The concept of ‘neuroinflammation’ has become
very popular recently [12–14], but our own work in this
field does not currently support a role for microgliosis as a
driver of the disease process [15]. The effective failure of
recent studies employing non-steroidal anti-inflammatory
drugs supports this notion [16, 17]. Thus, there are leads
and popular ideas but the big picture of PD pathogenesis is
still missing. A true understanding of PD and its subtypes
will require integrated knowledge from several system
biological levels, ranging from genomics to proteomics and
metabonomics as well as clinical data and neuroimaging.




The 94.CEL files used for this study have been deposited
at the National Center for Biotechnology Information,
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
projects/geo) with GEO Series accession number GSE8397
(scheduled release date: 1 January 2008). The patient
samples employed have been described previously [3].
This data set is based on Affymetrix HU_133A and
HU_133B gene chips set and has been extensively
validated over a period of 2 years using qRT-PCR, immu-
nocytochemistry and in situ hybridisation to cellularly
‘back-map’ sequences of interest [7, 8, 10, 18].
Data analysis procedures employed
In silico analyses were performed with the help of
programme packages from different suppliers. Our initial
microarray data analysis was performed using ArrayAssist
3.0 (Stratagene) but there were intermittent problems with
some versions of the software (3.2–3.4). We have repeated
our analysis using newer (4.0, 4.1; Linux and/or Windows)
and the latest version of this program (ArrayAssist 5.5 for
Windows, Stratagene). In addition, we have reproduced our
results using an independent software package for micro-
array analysis, PathwayStudio 5.0. The (GC-)RMA algo-
rithm which has become a gold standard for Affymetrix
microarray normalisation was applied in all cases. In
addition, PathwayAssist (Ariadne) and Pathway Architect
(Stratagene) were employed during phases of our work. For
ease of use, most software installations were performed in
virtual machines (VMware Workstation and Fusion, re-
spectively; http://www.vmware.com) and two virtual
machines were frequently run in parallel on Windows,
Linux, or Macintosh platforms. The ability to create virtual
machine ‘snap shots’ of critical stages of the analysis
proved invaluable for the backtracking of results and to
allow comparability over time. It proved essential in the
case of the most complex network analyses where software
stability proved to be a factor.
We have used the microarray data in a hypothesis
generating rather than hypothesis testing way (cf. [4, 10]).
Since our original predictions based on the ArrayAssist 3.0
dataset turned out to be very reliable with respect to sub-
sequent in situ tissue validation results, we have performed
our refined analysis by means of this programme following
extensive comparison with readings generated by the latest
versions of ArrayAssist 5.5 and PathwayStudio 5.0. Any-
one intending to reproduce our results is referred to the
original CEL files (GEO ID GSE8397).
The following original cases were excluded from our
refined analysis to obtain more homogeneous cohorts
taking newly obtained histological and expression data into
account: Con4, 8 and MS155 as well as the sample of
medial substantia nigra from PD22. Thus, nine control
nigra and 23 PD nigra samples remained in the study. To
find differentially expressed genes, the p value cut off was
kept at 0.001 (differential expression=1 log2). Multiple
testing corrections (FDR, Bonferroni) were carried out for
comparative purposes. The 892 top genes identified on the
basis of 1,145 probes are referred to as the ‘priority genes’.
Hierarchical clustering was executed on both rows and
columns using ArrayAssist 5.5 (Pearson centred distance
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metric, centroid linkage rule). Similarity images were
produced to visualise the quality of clustering results
(SI_Figure_1). In addition, self-organising map clustering
was performed on both rows and columns using a
Euclidean distance metric in ArrayAssist 5.5 (maximum
number of iterations 50, number of grid rows 3, number of
grid columns 4, initial learning rate 0.03, initial neighbour-
hood radius 5, grid topology hexagonal, neighbourhood
type bubble).
For finding cell processes regulated by the differentially
expressed genes, PathwayStudio software (version 5.0) was
used. The 164 top up-regulated priority genes showing a
differential expression >1 log2 were selected and the find
common targets algorithm was employed in the build
pathway tool setting the cell process filter option. The
procedure was repeated for diseases entity type. Cell
processes and disease conditions showing the highest
number of biological associations, i.e. the strongest prob-
abilistic relationship based on literature evidence to the
group of 164 top up-regulated priority genes were selected.
Furthermore, known interactions between all 892 dysregu-
lated genes were identified using the ResNet 5.0 database
of molecular interactions which has been derived from the
published literature by means of a natural language
processing technology called Medscan [19]. A filter for
the parameters, promoter binding, expression and regula-
tion was applied in the latter case.
For additional validation, the commercial PathArt data-
base (PathwayAssist plug-in, Jubilant Biosys) containing a
large number of manually curated pathways was queried. A
number of GEO datasets (e.g. astrocytes and microglia in
culture) were downloaded to evaluate cell-type specificity
of expression of individual priority genes. A search for
novel secreted biomarkers was also performed of which
NPTX2 [8] may be one.
To retrieve known drug interactions of the 892 priority
genes, more than 9,000,000 database objects were checked
in ResNet 5.0 (PathwayStudio 5.0). Subsequently, all
known interactions of individual relevant drugs contained
in ResNet 5.0 were retrieved and the results overlaid with
the set of priority genes. Drugs scoring high in terms of the
number of their known interactions with the 892 priority
genes were identified and the relationship to PD analysed
employing the PubMed database (http://www.ncbi.nlm.nih.
gov/sites/entrez).
Results
The extended set of 892 PD priority genes
Screening of histological and clinical parameters combined
with iterative cycles of data mining enabled us to identify
the most comparable cases in the cohorts which are detailed
in SI_Figure_1. The number of highly significantly dysre-
gulated genes (p<0.001) increased from 429 (570 probes)
to 892 (1,145 probes) while 97% of the originally identified
genes [3] were confirmed. The complete list of all 892 PD
priority genes is provided in SI_Table_1a. It should be
mentioned that there are still some sequences that show
highly significant dysregulation in PD on which there is no
information available from ResNet 5.0, the IDconverter
database [20] or NetAffx. However, all 1,145 probes
(SI_Tables_1b&c) were used for the clustering (Fig. 1 and
SI_Figure_1). Information on the 1,145 Affymetrix probes
available from the public IDconverter database is provided
in SI_Table_1d. SI_Table_1e shows the probe informa-
tion not found in IDConverter or the ResNet database,
respectively, that was obtained via NetAffx (http://
www.affymetrix.com/analysis/index.affx). Thirty-one
priority genes have been previously designated PD can-
didate genes (http://www.pdgene.org/) (SI_Table_1f), and
it is worth noting that 33 are considered AD candidate
genes as well (SI_Table_1g) with HSPA1A, HSPA1B,
HTR2A, KCNJ6, SLC6A3, SNCA, SNCG, TF and
UCHL1 being present in both lists. A PubMed search
revealed that another 10 priority genes have known functional
links to PD (SI_Table_1h). Finally, ‘whole genome/whole
human body’ clustering using an independent data set
derived from 64 different organ samples which is based
on Affymetrix Human Genome U133 Plus 2.0 arrays
allowed categorical separation of all nervous tissue
samples including three different ganglia (SI_Figure_2).
Gene ontology and pathway analysis of the differentially
expressed genes
The statistically most significant overlap (Fisher Exact
test) between the 892 priority genes and GO groups
was found for GO ID 0016020 (membrane) and GO IDs
0005515/0045308 (protein binding or protein degrada-
tion tagging activity, respectively). Further details are
provided in the supplemental material (SI_Table_2). The
main cell processes predicted to be influenced by the
top up-regulated priority genes (164 genes showing dif-
ferential expression >1 log2) are illustrated in Fig. 2a.
A hyperlinked version of this figure providing details
on all genes and their interactions is available online
(SI_Figure_3a). A search of 192 canonical pathways
and 555 signalling pathways in PathwayStudio 5.0
yielded the RET_HSF1 signalling pathway which shares
six priority genes as the highest ranking result (SI_T-
able_3, SI_Pathway_1).
Predicted interactions of a subset of the 892 priority
genes are shown in Fig. 3. A total of 417 known
connections were retrieved from ResNet. This figure is
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provided for orientation purposes. Hyperlinked per-
mutations of this figure showing details of all genes
and their interactions are available online (SI_Figure_4).
Known components of Lewy bodies and how they relate
to the group of priority genes are presented in Fig. 4. The
probes for most of these components were found to cluster
together in the self-organising map shown in SI_Figure_5.
A hyperlinked version of Fig. 4 with expression values
overlaid is available online (SI_Figure_6). Interactions of
known PD genes with the priority genes of this study are
demonstrated in Fig. 5 (SI_Figure_7).
We did not observe an effect for gender (cf. [21]).
Hierarchical clustering of the male and female PD patients
on the basis of the expression values of the 892 priority
genes did not separate the groups nor did a whole genome
clustering omitting sex chromosomal sequences.
Fig. 1 Dendrogram showing
the results of unsupervised hier-
archical clustering of the 1,145
probes encompassing the 892
priority genes (corresponding
Affymetrix probe IDs and ex-
pression data are provided
online in SI_Figure_1). The al-
gorithm separates the control
(left) from the Parkinson’s dis-
ease group (right) (rows: red,
expression above average;
black, average expression;
green, below average). An ex-
planation of sample designa-
tions, patient data and a
quantitative colour code are also
provided in SI_Figure_1
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Fig. 2 a Cell processes predicted to be influenced by the top up-
regulated priority genes (164 genes showing a differential expression
>1 log2) based on in silico analysis employing the ResNet database
(PathwayStudio 5.0, Ariadne). P and expression values of all 1,145
probes can be found in SI_Table_1c. An online version of this figure
with hyperlinks is provided as SI_Figure_3a. b The three disease
conditions showing the strongest biological association with the group
of top up-regulated priority genes which may serve as drivers of the
disease process underlying PD. In silico analysis was performed
employing the ResNet database of molecular interactions (Pathway-
Studio 5.0, Ariadne). An online version of this figure with hyperlinks
is provided as SI_Figure_3b
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Fig. 3 Hypothetical ‘super pathway’ not stratified for cell type
illustrating known direct interactions between the 892 PD priority
genes (regulation, expression and promoter binding only). A total of
417 interactions (relations) are shown and any unlinked entities were
removed. Display style: by effect; cellular layout; colour codes:
promoter binding, violet; green, positive regulation; red, negative
regulation; grey and/or broken lines, unknown (Resnet 5.0 database,
unedited). Blue shading around selected genes indicates their
involvement in the cellular process and disease conditions depicted
in Fig. 2a and b, respectively. Permutations of this figure with
hyperlinks are provided online as SI_Figures_4a-c
6 Neurogenetics (2008) 9:1–13
Relationship to diseases and drug interactions
A search of the ResNet database identified three disease con-
ditions that showed the strongest probabilistic relationship to
the group of top up-regulated priority genes, cancer, diabetes
and inflammation as illustrated in Fig. 2b. A hyperlinked
version of this figure providing details on all genes and their
interactions is available online (SI_Figure_3b). Known drug
interactions of some of the priority genes were retrieved
from the ResNet 5.0 database through checking of more
than 9,000,000 database objects. It is noteworthy that drugs
such as clozapine, cocaine and haloperidol, which are used
in the treatment of PD or which cause Parkinsonian side
effects, appear to interact with a large number of PD priority
genes (SI_Figure_8). A search of the ResNet database also
yielded information on the interactions of two cytostatic
drugs, paclitaxel and vincristine with the priority genes
identified in this study (SI_Pathways_2&3). Both paclitaxel
and vincristine have been reported to induce parkinsonian
side effects [22, 23].
Fig. 4 Neuronal pathway containing proteins found in Lewy bodies
[11]. Priority genes of this study are marked by the blue shading. An
online version of this figure with hyperlinks and an overlay of
expression values is provided as SI_Figure_6. Symmetrical layout,
display by effect (PathwayStudio)
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‘Hub’ vs ‘peripheral’ genes
A number of genes known to have numerous interactions
with other genes were found amongst the priority genes.
These represent so-called network ‘hubs’ and include
HSPA1A, NFKBIA, CDC42, GSK3B, ACHE, AGTR1,
IGF1R and TH as well as about 200 others (50 to >1,600
connectivities). Figure 2a and b contain a number of hubs.
However, almost 30% of the priority genes have no known
interactions according to the ResNet 5.0 database although
the cellular localisation is known in some instances. Such
genes may be called ‘peripheral’ genes of the human
interactome [24, 25]. Apparently, peripheral priority genes
with still unknown pathway connections and cellular
localisation are ACTR10, ANKRD29, ANKRD34,
ANKRD50, ARMCX4, ARRDC2, ASMTL, ATAD1,
Fig. 5 Interactions of known PD genes (marked yellow) with the
priority genes of this study. Expression value overlay: red indicates
up- regulation and blue indicates down-regulation in PD nigra. An
online version of this figure with hyperlinks and an overlay of
significance values is provided as SI_Figure_7. Cellular layout,
display by effect (ResNet)
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BLOC1S2, CAP2, CCDC4, CCDC85A, CKMT1A,
CNIH3, DBNDD1, DCUN1D4, DIRAS2, DOPEY1,
EHBP1, ELMOD1, FARSLB, FBXO9, FHOD3, GABAR-
APL3, GARNL4, GPRASP2, GPRIN3, GUSBP1,
HISPPD1, HNRPUL2, IPW, KLHL1, KRT222P, LRRC49,
LRRC55, LYNX1, MANEAL, MAP1LC3A, MAP9,
MGC22265, MGC39606, MGC4677, MIA3, MRC1L1,
NCDN, NGFRAP1L1, NRIP3, NUDT11, OCIAD2,
OGDHL, OSBPL10, PCYOX1L, PFAAP5, PGM2L1,
PLCXD3, PNMA6A, PRKY, PRMT8, PRPS1, RFPL1S,
RUTBC2, SLC35F1, SNX10, SNX25, TAGLN3,
TBC1D24, TBC1D9, TMEM130, TMEM132B, TMEM35,
TRIM4, TRIM9, TSGA14, TTC7B, TUBB2B, TUBB3,
UBPH, USP34, WDR47, XKR4, ZNF204.
Up-regulated peripheral genes are shown in Table 1.
Following the above criteria, a number of Lewy body
components and genes known to interact with the estab-
lished PD genes seem peripheral to main brain metabolic
pathways but their exact status remains to be determined.
Discussion
Our study reveals a significant up-regulation of substantia
nigra genes in PD which have known biological associa-
tions with cancer, diabetes and inflammation. This includes
major ‘hub’ genes [24–26] such as p53, somatic mutations
of which can cause cancer. This is of note as p53 forms part
of a molecular network that integrates tumour suppression
and ageing [27]. DJ-1 is another cancer- and Parkinson’s
disease-associated protein [28], and it is of special interest
in the present context that the ubiquitin-proteasomal
pathway has an established role in neoplastic processes
[29]. Furthermore, both parkin and PINK1 might be tumour
suppressor genes, and it has been suggested that although
cancer is rare in PD, unraveling the link between PD and
cancer [30–31] may open a therapeutic window for both
diseases [32]. The finding of a molecular biological
association between diabetes and PD is not truly surprising
either [33–37]. Thirdly, the link of PD with inflammation
which emerges from our unsupervised analysis seems
almost expected considering the very lively debate of this
topic in the literature. The whole genome transcriptome
data presented here certainly justify additional scrutiny of
the underlying mechanisms in relation to PD pathogenesis.
The problem of defining what causes PD at a system
level has become more complex with the recent finding that
disease-relevant genes may reside at the periphery of
disease networks. It is interesting to note that the neighbour
of a disease node appears more likely to be another disease
protein, which also preferentially interacts with other
disease nodes [38]. Proteins that are associated with the
same disease show a 10-fold increased tendency to interact
with each other than those not associated with the same
disease [26]. This should direct our attention also to genes
that do not form major network hubs but which are either
likely to be involved in PD on cell biological grounds (e.g.
Lewy body components) or which interact with PD causing
genes. A significant fraction of the genes identified in this
study still represent functionally ill-characterised entities.
The on-line material of this manuscript illustrates some
of the pathways and biological association networks that
emerge from our analysis. Networks are now recognized to
pervade all aspects of human biology and the question
where function lies within a cell is shifting from a simple
focus on genes to the understanding that behind each
cellular function there is a discernible network module
consisting of genes, transcription factors, RNAs, enzymes
and metabolites [39]. However, ‘network medicine’ is still
in its infancy and the present study may be the first where
an iterative multidimensional tissue analysis approach,
http://www.neurogenetics.net/Multidimensional.html, has
been applied to a human neurological disorder. The
ultimate goal of such analyses is the precise cellular
localisation of all expressed human disease genes in their
affected tissues. The present PD dataset has so far yielded
two novel components of Lewy bodies [7, 8] but much
more back-mapping work will need to be performed.
For instance, the exact mechanism of cell death in PD is
still unknown [40]. Recent evidence has suggested that one
mechanism linked to the death of terminally differentiated
neurons is aberrant re-entry into the cell cycle, and possible
connections between oxidative stress and unscheduled cell
cycle re-entry in PD have been proposed [41]. However, as
neuroscientists, we may have to move beyond the descrip-
tion of the cell cycle that has been propagated by those in
the cancer field because the regulation of the cell cycle in
the neuron is much more nuanced (K Herrup, http://www.
alzforum.org/new/detailprint.asp?id=1688). This raises the
possibility that some of the data supporting cell processes
such as mutagenesis in this study may have to be re-read
and interpreted in a modified way. It is worth noting in this
context that absence of RET signalling in mice causes
progressive and late degeneration of the nigrostriatal system
[42]. We would also like to point out that the present study
provides additional evidence for the importance of changes
in the neuronal cytoskeleton in PD [43–44] because
neurofilament subunit as well as microtubuli-associated
protein genes were found to be highly dysregulated.
Dysregulation of signal transduction, heat shock and
synaptic proteins also featured very prominently.
The view that the 892 nigral genes presented here are
relevant for sporadic PD is supported by the finding that
their pattern of expression is characteristic of nervous tissue
(SI_Figure_2). It is further clear from our data that the
human substantia nigra in PD does not represent dead tissue
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Table 1 Up-regulated ‘peripheral’ priority genes
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but that there is an active ongoing disease process under-
standing of which may hold the key to halting PD. The
dysregulated priority genes may reside at the core of the
disease process and could serve as novel targets for therapeutic
intervention. This idea is supported by the observation that
a number of priority genes interact with drugs whose actions
are associated with a Parkinsonian clinical phenotype.
The uncertainty whether inflammatory processes truly
represent a causative factor in the aetiology of PD [45]
requires an answer. Our own work and that of others suggests
a direct role of primary glial degeneration in the pathogenetic
process underlying PD [10, 46]. This means that PD extends
beyond the neuron. The disease is also not confined to the
substantia nigra anatomically. Detailed cellular back-map-
ping of all priority genes to brain tissue will help to settle
these questions. New algorithms are required to explain the
links of PD as defined in the living and in the microscope
with the underlying high-throughput datasets.
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1c.png
SI_Figure_2 Hierarchical clustering of the 1,145 probes
using 64 whole genome array datasets (Affymetrix Human
Genome U133 Plus 2.0 arrays) representing individual
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morphonom.net/ng/ESM/f/Disease.html
SI_Figures_4a-c Online permutations of Fig. 3
Layout by cellular localisation with links http://www.
morphonom.net/ng/ESM/f/892.html
Symmetrical layout with links http://www.morphonom.
net/ng/ESM/f/892s.html
Hierarchical layout with links http://www.morphonom.
net/ng/ESM/f/892h.html
SI_Figure_5 Known components of Lewy bodies are
indicated by the blue highlighting (this figure is identical to
SI_Figure_1c except that it has a lower resolution) http://
www.morphonom.net/ng/ESM/f/SI_Figure_5.png
SI_Figure_6 Online version of Fig. 4 with expression
values overlaid (red indicates up- and blue indicates down-
regulation in PD nigra, respectively). The blue shading of
the priority genes has been replaced with yellow. http://
www.morphonom.net/ng/ESM/f/Lewy_Body.html
SI_Figure_7 Hyperlinked online version of Fig. 5. The
gene colours range in this figure indicates significance:
high, white; low, red. The blue shading indicates that the
respective gene is a priority gene. http://www.morphonom.
net/ng/ESM/f/PD_genes_interactions_with_892_direct_
no_DorCP.html
SI_Figures_8a-c Known drug interactions of some of
the priority genes as derived from the ResNet 5.0 database
(more than 9,000,000 database objects were checked). It is
noteworthy that drugs such as clozapine, cocaine and
haloperidol which are used in the treatment of PD or which
cause Parkinsonian side effects appear to interact with an







SI_Pathway_1 This signalling pathway was identified
based on a search of 192 canonical pathways and 555
signalling pathways in PathwayStudio 5.0 and ranked
highest (also see SI_Table_3). Six priority genes are
represented in this pathway and are marked by the blue
shading. http://www.morphonom.net/ng/ESM/p/RET_
HSF1_signaling_pathway.html
SI_Pathway_2 Interactions of the cytostatic drug, pacli-
taxel with a total of 13 priority genes (blue shading) are
shown. Display by effect. Hierarchical layout. http://www.
morphonom.net/ng/ESM/p/paclitaxel_interactions.html
SI_Pathway_3 Interactions of the cytostatic drug,
vincristine with 3 priority genes (violet shading, bottom of
figure) are illustrated. Red shaded genes also showed
dysregulation in the PD nigra (p<0.001). Display by
references count (darker blue indicates a larger number
of references supporting the respective connection).
Hierarchical layout. http://www.morphonom.net/ng/ESM/
p/vincristine_interactions.html
SI_References_1 References for SI_Table_1h http://
www.morphonom.net/ng/ESM/r/SI_References_1.rtf
SI_References_2 Designations and code numbers for
SI_Figure_2 http://www.morphonom.net/ng/ESM/r/SI_
References_2.rtf
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